middle.news

Actinogen Clears Path to XanaMIA Alzheimer’s Trial Readout

10:33am on Tuesday 17th of November, 2026 AEDT • Biotechnology
Read Story

Actinogen Clears Path to XanaMIA Alzheimer’s Trial Readout

10:33am on Tuesday 17th of November, 2026 AEDT
Key Points
  • Immediate ASX suspension pending XanaMIA topline results
  • Additional clinical trial data received on 17 November
  • 247-patient phase 2b/3 trial testing Xanamem 10 mg
  • Primary endpoint is the CDR-SB dementia scale
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Actinogen Medical (ASX:ACW)
OPEN ARTICLE